Market Research Logo

Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK,

Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, France, China, India, Japan)

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Hepatitis B Treatment Market by Type (Therapeutics and Vaccines), By End-User (Male and Female) for the regions (North America, Europe, Asia—Pacific and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan).

Over the recent years, the global Hepatitis B Treatment industry has been driven by the increasing number of patients diagnosed with Chronic Hepatitis B which results in severe complications, rising awareness about the consequences of viral infection, rigorous efforts to eliminate the viral infection, improving surveillance and diagnostic facilities, significant number of drugs in pipeline with better efficacy coupled with emerging vaccines with lower dosage and better effectiveness. Globally, the growth in Hepatitis B Treatment market is driven by backed by growing middle class population group demanding better drugs to improve lifestyle.

According to Azoth Analytics research report “Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, France, China, India, Japan)”, global market is projected to display a growth represented by a CAGR of 5.30% by value during 2017 – 2022, chiefly driven by increase in healthcare spending and improving access to diagnosis for Chronic Hepatitis B, increasing risk of severe complications due to Hepatitis B virus.

Among the type of treatment, therapeutics accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with chronic Hepatitis B virus with unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.

The report titled, “Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, France, China, India, Japan)” has covered and analysed the potential of Hepatitis B Treatment Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global Hepatitis B Treatment market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

  • Global Hepatitis B Treatment Market
  • Analysis By Type (Therapeutics and Vaccines)
  • Analysis By End-User (Male and Female)
Regional Markets – North America, Europe, APAC, ROW (Actual Period: 2012-2016, Forecast Period: 2017-2022)
  • By Type (Therapeutics and Vaccines)
  • By End-User (Male and Female)
Country Analysis - United States, Canada, United Kingdom, Germany, France, China, India, Japan (Actual Period: 2012-2016, Forecast Period: 2017-2022)
  • By Type (Therapeutics and Vaccines)
  • By End-User (Male and Female)
Other Report Highlights
  • Market Dynamics – Trends, Drivers, Challenges, Policy and Regulation
  • Company Analysis – Merck and Co; Gilead Sciences; Novartis AG; GlaxoSmithKline, plc; Hoffmann- La Roche; Bristol-Myers Squibb


1. Research Methodology
2. Executive Summary
3. Strategic Recommendation
3.1. Asia Pacific Region to witness the fastest growth for Hepatitis B market in the forecast period
3.2. Therapeutic segment witnessing fastest growth
4. Hepatitis B Treatment Market: Product Outlook
Table A: Causes of Hepatitis B
Table B: HBV Approved Therapies
Table C: Globally Approved HBV Monovalent Vaccines
5. Global Hepatitis B Treatment Market: Growth and Forecast
5.1. Global Hepatitis B Treatment Market, By Value (2012-2016)
Table 1: Global Hepatitis B Treatment Market Size, By Value, 2012-2016 (USD Million)
Table 2: Number of patients with Hepatitis B Virus (HBsAg) infection by WHO region, 2015 (In Million)
Table 3: Global Healthcare Expenditure, 2012-2016 (In Trillion)
5.2. Global Hepatitis B Treatment Market, By Value (2017-2022)
Table 4: Global Hepatitis B Treatment Market Size, By Value, 2017-2022 (USD Million)
5.3. Global Hepatitis B Treatment Market - By Type, By Value
5.3.1. Global Hepatitis B Treatment Market, By Value, % (2016)
Table 5: Global Hepatitis B Treatment Market Size, By Type, 2016 (%)
5.3.2. Global Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
Table 6: Global Hepatitis B Treatment Market Size, By Type, 2022 (%)
5.4. Global Hepatitis B Treatment Market, By Type, By Value (2012-2022)
Table 7: Global Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
5.4.1. Therapeutics, By Value (2012-2022)
5.4.2. Vaccines, By Value (2012-2022)
5.5. Global Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
Table 8: Global Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
5.5.1. Male, By Value (2012-2022)
5.5.2. Female, By Value (2012-2022)
Table 9: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
Table 10: Global Sales of Viread, By Value, 2015-2016 (USD Million)
Table 11: Global Hepatitis B Treatment Market Size, By Region, 2016 (%)
Table 12: Global Hepatitis B Treatment Market Size, By Region, 2022 (%)
6. North America Hepatitis B Treatment Market: Growth and Forecast
6.1. North America Hepatitis B Treatment Market, By Value (2012-2016)
Table 13: North America Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
6.2. North America Hepatitis B Treatment Market, By Value (2017-2022)
Table 13: North America Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Table 14: North America GDP, 2012-2015 (USD Trillion)
Table 15: North America GDP, By Select Country, 2016 (USD Trillion)
Table 16: Population aged 65 & above, 2012-2016 (% of total)
6.3. North America Hepatitis B Treatment Market - By Type, By Value
6.3.1. North America Hepatitis B Treatment Market, By Value, % (2016)
Table 17: North America Hepatitis B Treatment Market Size, By Type, 2016 (%)
6.3.2. North America Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
Table 18: North America Hepatitis B Treatment Market Size, By Type, 2022 (%)
6.4. North America Hepatitis B Treatment Market, By Type, By Value (2012-2022)
Table 19: North America Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
6.4.1. Therapeutics, By Value (2012-2022)
6.4.2. Vaccines, By Value (2012-2022)
6.5. North America Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
Table 20: North America Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
6.5.1. Male, By Value (2012-2022)
6.5.2. Female, By Value (2012-2022)
6.6. North America Hepatitis B Treatment Market: Country Analysis (U.S., Canada)
6.6.1. North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
Table 21: North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
6.6.2. North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
Table 22: North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
6.7. U.S. Hepatitis B Treatment Market: Growth and Forecast
6.7.1. U.S. Hepatitis B Treatment Market, By Value (2012-2016)
Table 23: U.S. Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
6.7.2. U.S. Hepatitis B Treatment Market, By Value (2017-2022)
Table 23: U.S. Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Table 24: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Table 25: Reported acute (new) cases of Hepatitis B Virus in U.S., (2012-2015)
Table 26: Incidences rate of acute Hepatitis B in U.S., By sex (2012-2015)
Table 27: Incidence of acute Hepatitis B in U.S., By age group, (2012-2015)
6.8. U.S. Hepatitis B Treatment Market - By Type, By Value
Table 28: U.S. Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
6.8.1. Therapeutics, By Value (2012-2022)
6.8.2. Vaccines, By Value (2012-2022)
6.9. U.S. Hepatitis B Treatment Market - By End-User, By Value
Table 29: U.S. Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
6.9.1. Male, By Value (2012-2022)
6.9.2. Female, By Value (2012-2022)
Table 30: Market Share of HBV approved Drugs in U.S., 2016 (% Share)
6.10. Canada Hepatitis B Treatment Market: Growth and Forecast
6.10.1. Canada Hepatitis B Treatment Market, By Value (2012-2016)
Table 31: Canada Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
6.10.2. Canada Hepatitis B Treatment Market, By Value (2017-2022)
Table 31: Canada Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Table 32: Canada Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Table 33: Canada Life Expectancy at birth rate (Years), 2012-2015
Table 34: Prevalence of Hepatitis B in Canada, (Patients per 100,000 (2012-2016)
Table 35: Number of Hepatitis B Patients, Canada, (2013-2016)
Table 36: Prevalence of Hepatitis B among Male population, Canada, (Patients per 100,000) (2012-2016)
Table 37: Prevalence of Hepatitis B among Female population, Canada, (Patients per 100,000) (2012-2016)
6.11. Canada Hepatitis B Treatment Market - By Type, By Value
Table 38: Canada Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
6.11.1. Therapeutics, By Value (2012-2022)
6.11.2. Vaccines, By Value (2012-2022)
6.12. Canada Hepatitis B Treatment Market - By End-User, By Value
Table 39: Canada Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
6.12.1. Male, By Value (2012-2022)
6.12.2. Female, By Value (2012-2022)
7. Europe Hepatitis B Treatment Market: Growth and Forecast
7.1. Europe Hepatitis B Treatment Market, By Value (2012-2016)
Table 40: Europe Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
7.2. Europe Hepatitis B Treatment Market, By Value (2017-2022)
Table 40: Europe Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Table 41: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Table 42: European Union Life Expectancy at birth rate (Years), 2012-2015
Table 43: Reported Hepatitis B Cases, Number & Rate per 100,000 populations, EU/EEA, 2012-2015
Table 44: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
Table 45: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
7.3. Europe Hepatitis B Treatment Market - By Type, By Value
7.3.1. Europe Hepatitis B Treatment Market, By Value, % (2016)
Table 46: Europe Hepatitis B Treatment Market Size, By Type, 2016 (%)
7.3.2. Europe Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
Table 47: Europe Hepatitis B Treatment Market Size, By Type, 2022 (%)
7.4. Europe Hepatitis B Treatment Market, By Type, By Value (2012-2022)
Table 48: Europe Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
7.4.1. Therapeutics, By Value (2012-2022)
7.4.2. Vaccines, By Value (2012-2022)
7.5. Europe Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
Table 49: Europe Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
7.5.1. Male, By Value (2012-2022)
7.5.2. Female, By Value (2012-2022)
7.6. Europe Hepatitis B Treatment Market: Country Analysis (U.K., Germany, France)
7.6.1. Europe Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
Table 50: Europe Hepatitis B Treatment, Country Share, 2016 (% of Total)
7.6.2. Europe Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
Table 51: Europe Hepatitis B Treatment, Country Share, 2022 (% of Total)
7.7. U.K. Hepatitis B Treatment Market: Growth and Forecast
7.7.1. U.K. Hepatitis B Treatment Market, By Value (2012-2016)
Table 52: U.K. Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
7.7.2. U.K. Hepatitis B Treatment Market, By Value (2017-2022)
Table 52: U.K. Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Table 53: U.K. Population 65 Years & Above (% of Total), 2012-2016
Table 54: U.K. Life Expectancy at birth rate (Years), 2012-2015
Table 55: U.K. Women Population, 2012-2016
Table 56: U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Table 57: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Table 58: Number of Hepatitis B Patients, (2013-2016)
Table 59: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Table 60: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
7.8. U.K. Hepatitis B Treatment Market - By Type, By Value
Table 61: U.K. Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
7.8.1. Therapeutics, By Value (2012-2022)
7.8.2. Vaccines, By Value (2012-2022)
7.9. U.K. Hepatitis B Treatment Market - By End-User, By Value
Table 62: U.K. Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
7.9.1. Male, By Value (2012-2022)
7.9.2. Female, By Value (2012-2022)
7.10. Germany Hepatitis B Treatment Market: Growth and Forecast
7.10.1. Germany Hepatitis B Treatment Market, By Value (2012-2016)
Table 63: Germany Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
7.10.2. Germany Hepatitis B Treatment Market, By Value (2017-2022)
Table 63: Germany Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Table 64: Germany Population 65 Years & Above (% of Total), 2012-2016
Table 65: Germany Life Expectancy at birth rate (Years), 2012-2015
Table 66: Germany Women Population, 2012-2016
Table 67: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Table 68: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Table 69: Number of Hepatitis B Patients, (2013-2016)
Table 70: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Table 71: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
7.11. Germany Hepatitis B Treatment Market - By Type, By Value
Table 72: Germany Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
7.11.1. Therapeutics, By Value (2012-2022)
7.11.2. Vaccines, By Value (2012-2022)
7.12. Germany Hepatitis B Treatment Market - By End-User, By Value
Table 73: Germany Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
7.12.1. Male, By Value (2012-2022)
7.12.2. Female, By Value (2012-2022)
7.13. France Hepatitis B Treatment Market: Growth and Forecast
7.13.1. France Hepatitis B Treatment Market, By Value (2012-2016)
Table 74: France Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
7.13.2. France Hepatitis B Treatment Market, By Value (2017-2022)
Table 74: France Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Table 75: France Population 65 Years & Above (% of Total), 2012-2016
Table 76: France Life Expectancy at birth rate (Years), 2012-2015
Table 77: France Women Population, 2012-2016
Table 78: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Table 79: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Table 80: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Table 81: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
7.14. France Hepatitis B Treatment Market - By Type, By Value
Table 82: France Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
7.14.1. Therapeutics, By Value (2012-2022)
7.14.2. Vaccines, By Value (2012-2022)
7.15. France Hepatitis B Treatment Market - By End-User, By Value
Table 83: France Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
7.15.1. Male, By Value (2012-2022)
7.15.2. Female, By Value (2012-2022)
8. Asia-Pacific Hepatitis B Treatment Market: Growth and Forecast
8.1. Asia-Pacific Hepatitis B Treatment Market, By Value (2012-2016)
Table 84: Asia-Pacific Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
8.2. Asia-Pacific Hepatitis B Treatment Market, By Value (2017-2022)
Table 84: Asia-Pacific Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Table 85: Mortality due to Viral Hepatitis in South-East Asia region, 2015
8.3. Asia-Pacific Hepatitis B Treatment Market - By Type, By Value
8.3.1. Asia-Pacific Hepatitis B Treatment Market, By Value, % (2016)
Table 86: Asia-Pacific Hepatitis B Treatment Size, By Type, 2016 (%)
8.3.2. Asia-Pacific Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
Table 87: Asia-Pacific Hepatitis B Drug Market Size, By Type, 2022 (%)
8.4. Asia-Pacific Hepatitis B Treatment Market, By Type, By Value (2012-2022)
Table 88: Asia-pacific Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
8.4.1. Therapeutics, By Value (2012-2022)
8.4.2. Vaccines, By Value (2012-2022)
8.5. Asia-Pacific Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
Table 89: Asia-Pacific Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
8.5.1. Male, By Value (2012-2022)
8.5.2. Female, By Value (2012-2022)
8.6. Asia-Pacific Hepatitis B Treatment Market: Country Analysis (Japan, China, India)
8.6.1. Asia-Pacific Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
Table 90: Asia-Pacific Hepatitis B Treatment, Country Share, 2016 (% of Total)
8.6.2. Asia-Pacific Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
Table 91: Asia-Pacific Hepatitis B Treatment, Country Share, 2022 (% of Total)
8.7. Japan Hepatitis B Treatment Market: Growth and Forecast
8.7.1. Japan Hepatitis B Treatment Market, By Value (2012-2016)
Table 92: Japan Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
8.7.2. Japan Hepatitis B Treatment Market, By Value (2017-2022)
Table 92: Japan Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Table 93: Japan Population 65 Years & Above (% of Total), 2012-2016
Table 94: Japan Life Expectancy at birth rate (Years), 2012-2015
Table 95: Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Table 96: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Table 97: Number of Hepatitis B Patients, 2013-2016)
Table 98: Prevalence of Hepatitis B among Male population (Patients per 100,000 (2012-2016)
Table 99: Prevalence of Hepatitis B among Female population (Patients per 100,000 (2012-2016)
8.8. Japan Hepatitis B Treatment Market - By Type, By Value
Table 100: Japan Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
8.8.1. Therapeutics, By Value (2012-2022)
8.8.2. Vaccines, By Value (2012-2022)
8.9. Japan Hepatitis B Treatment Market - By End-User, By Value
Table 101: Japan Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
8.9.1. Male, By Value (2012-2022)
8.9.2. Female, By Value (2012-2022)
8.10. China Hepatitis B Treatment Market: Growth and Forecast
8.10.1. China Hepatitis B Treatment Market, By Value (2012-2016)
Table 102: China Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
8.10.2. China Hepatitis B Treatment Market, By Value (2017-2022)
Table 102: China Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Table 103: China Population 65 Years & Above (% of Total), 2012-2016
Table 104: China Life Expectancy at birth rate (Years), 2012-2015
Table 105: China Women Population, 2012-2016
Table 106: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Table 107: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Table 108: Number of Hepatitis B Patients, 2013-2016)
Table 109: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Table 110: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
8.11. China Hepatitis B Treatment Market - By Type, By Value
Table 111: China Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
8.11.1. Therapeutics, By Value (2012-2022)
8.11.2. Vaccines, By Value (2012-2022)
8.12. China Hepatitis B Treatment Market - By End-User, By Value
Table 112: China Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
8.12.1. Male, By Value (2012-2022)
8.12.2. Female, By Value (2012-2022)
8.13. India Hepatitis B Treatment Market: Growth and Forecast
8.13.1. India Hepatitis B Treatment Market, By Value (2012-2016)
Table 113: India Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
8.13.2. India Hepatitis B Treatment Market, By Value (2017-2022)
Table 113: India Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Table 114: India Population 65 Years & Above (% of Total), 2012-2016
Table 115: India Life Expectancy at birth rate (Years), 2012-2015
Table 116: India Women Population, 2012-2016
Table 117: India Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Table 118: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Table 119: Number of Hepatitis B Patients, 2013-2016)
Table 120: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Table 121: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
8.14. India Hepatitis B Treatment Market - By Type, By Value
Table 122: India Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
8.14.1. Therapeutics, By Value (2012-2022)
8.14.2. Vaccines, By Value (2012-2022)
8.15. India Hepatitis B Treatment Market - By End-User, By Value
Table 123: India Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
8.15.1. Male, By Value (2012-2022)
8.15.2. Female, By Value (2012-2022)
9. ROW Hepatitis B Treatment Market: Growth and Forecast
9.1. ROW Hepatitis B Treatment Market, By Value (2012-2016)
Table 124: ROW Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
9.2. ROW Hepatitis B Treatment Market, By Value (2017-2022)
Table 124: ROW Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Table 125: Prevalence of Hepatitis B in Brazil (Patients per 100,000 (2012-2016)
Table 126: Number of Hepatitis B Patients in Brazil, (2013-2016)
Table 127: Prevalence of Hepatitis B among Male population, in Brazil (Patients per 100,000) (2012-2016)
Table 128: Prevalence of Hepatitis B among Female population in Brazil (Patients per 100,000) (2012-2016)
Table 129: Prevalence of Hepatitis B in South Africa (Patients per 100,000 (2012-2016)
Table 130: Number of Hepatitis B Patients in South Africa, (2013-2016)
Table 131: Prevalence of Hepatitis B among Male population, in South Africa (Patients per 100,000) (2012-2016)
Table 132: Prevalence of Hepatitis B among Female population (Patients per 100,000), in South Africa (2012-2016)
10. Market Dynamics 10.1. Increasing prevalence of Liver diseases due to Hepatitis B
10.2. Increasing awareness about the Hepatitis B & HBV
10.3. Rising healthcare expenditure worldwide
Table 133: Global Healthcare Expenditure, 2012-2016 (In Trillion)
11. Market Restraints
12. SWOT Analysis – Hepatitis B Treatment Market
13. Porter’s Five Forces Analysis
14. Policy and Regulations
15. Global Hepatitis B Drugs Pipeline
Table D: Compounds in development for chronic Hepatitis B
16. Global Hepatitis B Treatment Market - Competitive Landscape
Table 134: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
Table 135: Global Sales of Viread, By, Region, By Value, 2015-2016 (USD Million)
17. Company Profiles
17.1. Merck and Co
Table 136: Merck & Co., Net Sales, 2012-2016 (In million USD)
Table 137: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)
Table 138: Merck & Co., Net Sales, By Geographic Location, % Share 2016
Table 139: Merck & Co., Net Revenue, By Business Segment, % Share 2016
17.2. Gilead Sciences
Table 140: Gilead Sciences Annual Revenue, 2014-2016 (USD Million)
Table 141: Gilead Sciences HBV Product Sales, 2014-2016 (USD Million)
Table 142: Gilead Sciences Revenue by Geographical, 2016 (%)
Table 143: Gilead Sciences Product Sales, 2016 (%)
17.3. Novartis AG
Table 144: Novartis Annual Revenue, 2014-2016 (USD Million)
Table 145: Innovative Medicine Net Sales, By Business Unit 2016 (%)
Table 146: Novartis Sales, By Region, 2016 (%)
Table 147: Novartis Sales, By Segment 2016 (%)
17.4. GlaxoSmithKline, plc
Table 147: Novartis Sales, By Segment 2016 (%)
Table 149: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)
Table 150: Glaxosmithkline Sales, By Region, 2016 (%)
Table 151: Glaxosmithkline, Sales, By Segment 2016 (%)
17.5. F.Hoffmann- La Roche
Table 152: F. Hoffmann-La Roche Ltd Annual Revenue, 2014-2016 (USD Million)
Table 153: F. Hoffmann-La Roche Ltd Segmental Break Up, By Revenue, By Business Division, 2016 (%)
Table 154: F. Hoffmann-La Roche Ltd Geographical Break Up, By Revenue, 2016 (%)
17.6. Bristol-Myers Squibb
Table 155: Bristol-Myers Squibb Company Annual Revenue, 2014-2016 (USD Million)
Table 156: Bristol-Myers Squibb Company Segmental Break Up, By Revenue, By Products, 2016 (%)
Table 157: Bristol-Myers Squibb Company Geographical Break Up, By Revenue, 2016 (%)
Table 158: Baraclude (entecavir), Annual Revenue, 2014-2016 (USD Million)
Table 159: Baraclude (entecavir), Segmental Break Up, By geographical segment, 2016 (%)
17.7. AbbVie Inc
Table 160: AbbVie Revenue, Segmental Break Up, 2016
Table 161: AbbVie Revenue, Geographical Break Up, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report